Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.23B 11.32B 10.62B 19.87B 1,322B 20.01B 134B 51.98B 651B 52.63B 51.5B 2,263B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.37B 10.53B 9.87B 18.48B 1,230B 18.61B 125B 48.33B 605B 48.93B 47.89B 2,104B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Compliance Officer 64 01/07/2019
Chief Tech/Sci/R&D Officer - 31/03/2022
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
01/04/25Issuer sale

Executive Vice President & CFO

75,024 0.0706%
01/04/25Issuer sale

Director

242,551 0.2281%
01/04/25Issuer sale

Chief Executive Officer

2,048,863 1.9269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+101.39% 14.02B
+0.33%-0.36%+19.66%-21.92% 62.05B
+0.20%-9.17%+58.54%+194.67% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.58%-58.97% 39.06B
-1.05%-1.73%+54.74%-33.09% 29.02B
+3.50%+28.15%+146.95%-48.51% 25.38B
-0.78%-9.50%+43.47%+59.06% 19.62B
+1.74%-0.39%-1.99%+126.64% 16.89B
-0.05%+0.23%+61.48%+104.74% 15.89B
Average +0.76%+2.50%+36.87%+46.14% 31.8B
Weighted average by Cap. +0.75%+1.65%+34.80%+39.92%

Financials

2023 2024
Net sales 464M 405M 375M 352M 658M 43.79B 663M 4.45B 1.72B 21.56B 1.74B 1.71B 74.95B 681M 594M 550M 516M 965M 64.21B 972M 6.52B 2.52B 31.6B 2.56B 2.5B 110B
Net income -140M -122M -113M -106M -198M -13.17B -199M -1.34B -518M -6.48B -524M -513M -22.54B -74.68M -65.13M -60.29M -56.56M -106M -7.04B -107M -715M -277M -3.47B -280M -274M -12.05B
Net Debt -481M -420M -388M -364M -682M -45.36B -687M -4.61B -1.78B -22.33B -1.81B -1.77B -77.63B -984M -858M -794M -745M -1.39B -92.81B -1.4B -9.42B -3.65B -45.68B -3.69B -3.61B -159B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!